Sustained release intraocular drug delivery systems
First Claim
1. A sustained-release intraocular drug delivery system comprising:
- a therapeutic component comprising an antiangiogenic oligonucleotide or polypeptide component; and
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye.
0 Assignments
0 Petitions
Accused Products
Abstract
Biocompatible intraocular drug delivery systems include a anti-angiogenic macromolecular therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three dimensional structure but retain its therapeutic activity. The therapeutic agent contains a component selected from the group consisting of anti-angiogenesis peptides and nucleic acid agents. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
208 Citations
57 Claims
-
1. A sustained-release intraocular drug delivery system comprising:
-
a therapeutic component comprising an antiangiogenic oligonucleotide or polypeptide component; and
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 47, 48, 49, 50, 51, 52, 53, 54)
-
-
34. A sustained-release intraocular drug delivery system comprising:
-
a therapeutic component comprising an antiangiogenic polypeptide component; and
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye. - View Dependent Claims (35, 36, 37, 41, 42, 43, 44, 45, 46)
-
- 38. The system of claim 38 wherein the artificial antibody comprises a scaffold region based upon a fibronectin.
-
55. A sustained-release intraocular drug delivery system comprising:
-
a therapeutic component comprising an antiangiogenic oligonucleotide or polypeptide component, wherein the therapeutic component is siRNA Z; and
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye.
-
-
56. A sustained-release intraocular drug delivery system comprising:
-
a therapeutic component comprising an antiangiogenic oligonucleotide or polypeptide component, wherein the therapeutic component is an siRNA capable of silencing expression of PDGF; and
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye.
-
-
57. A sustained-release intraocular drug delivery system comprising:
-
a therapeutic component comprising an antiangiogenic polypeptide component, wherein the therapeutic component is selected from the group consisting of C7S100 and C7C100; and
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye.
-
Specification